Denali Therapeutics Stock Performance
| DNLI Stock | USD 24.50 0.19 0.77% |
Denali Therapeutics has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 2.46, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Denali Therapeutics will likely underperform. Denali Therapeutics right now shows a risk of 3.44%. Please confirm Denali Therapeutics sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to decide if Denali Therapeutics will be following its price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Very Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Denali Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly strong essential indicators, Denali Therapeutics is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Actual Historical Performance (%)
One Day Return 2.19 | Five Day Return 4.34 | Year To Date Return 17.95 | Ten Year Return 17.62 | All Time Return 17.62 |
1 | Myriad Down 4.8 percent Since Last Earnings Report Can It Rebound | 09/05/2024 |
2 | Disposition of 1020 shares by Sato Vicki L of Denali Therapeutics at 30.0 subject to Rule 16b-3 | 09/13/2024 |
3 | Acquisition by Ho Carole of 161160 shares of Denali Therapeutics at 20.33 subject to Rule 16b-3 | 09/25/2024 |
4 | Sanofi, Denali face trial setback for neuro drug | 10/11/2024 |
5 | The five-year returns have been notable for Denali Therapeutics shareholders despite underlying losses increasing | 10/17/2024 |
6 | Disposition of 40000 shares by Ryan Watts of Denali Therapeutics at 27.69 subject to Rule 16b-3 | 10/18/2024 |
7 | Denali Therapeutics Inc. May Report Negative Earnings Know the Trend Ahead of Q3 Release | 10/29/2024 |
8 | Disposition of 3080 shares by Sato Vicki L of Denali Therapeutics at 27.07 subject to Rule 16b-3 | 11/01/2024 |
9 | Wellington Management Group LLPs Strategic Acquisition in Denali Therapeutics Inc | 11/08/2024 |
10 | Disposition of 47165 shares by Schenkein David P of Denali Therapeutics at 18.0 subject to Rule 16b-3 | 11/11/2024 |
11 | BofA raises Denali Therapeutics target to 34 on BLA plans | 11/12/2024 |
12 | Vicki L. Sato Sells 1,020 Shares of Denali Therapeutics Inc. Stock | 11/14/2024 |
13 | Acquisition by Sato Vicki L of 17901 shares of Denali Therapeutics at 18.56 subject to Rule 16b-3 | 11/19/2024 |
14 | Denali Therapeutics Inc. Receives 38.90 Consensus Target Price from Brokerages - MarketBeat | 11/21/2024 |
| Begin Period Cash Flow | 219.5 M |
Denali |
Denali Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,451 in Denali Therapeutics on August 28, 2024 and sell it today you would lose (1.00) from holding Denali Therapeutics or give up 0.04% of portfolio value over 90 days. Denali Therapeutics is currently generating 0.0579% in daily expected returns and assumes 3.4433% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Denali, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Denali Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Denali Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Denali Therapeutics, and traders can use it to determine the average amount a Denali Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0168
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | DNLI | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.44 actual daily | 30 70% of assets are more volatile |
Expected Return
| 0.06 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Denali Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Denali Therapeutics by adding it to a well-diversified portfolio.
Denali Therapeutics Fundamentals Growth
Denali Stock prices reflect investors' perceptions of the future prospects and financial health of Denali Therapeutics, and Denali Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Denali Stock performance.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 2.77 B | ||||
| Shares Outstanding | 143.92 M | ||||
| Price To Earning | 60.91 X | ||||
| Price To Book | 2.70 X | ||||
| Price To Sales | 3,339 X | ||||
| Revenue | 330.53 M | ||||
| Gross Profit | (250.27 M) | ||||
| EBITDA | (179.97 M) | ||||
| Net Income | (145.22 M) | ||||
| Cash And Equivalents | 1.07 B | ||||
| Cash Per Share | 8.66 X | ||||
| Total Debt | 52.24 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.20 X | ||||
| Book Value Per Share | 9.17 X | ||||
| Cash Flow From Operations | (357.99 M) | ||||
| Earnings Per Share | (2.76) X | ||||
| Market Capitalization | 3.55 B | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (1.12 B) | ||||
| Working Capital | 986.15 M | ||||
| Current Asset | 281.74 M | ||||
| Current Liabilities | 10.46 M | ||||
About Denali Therapeutics Performance
By evaluating Denali Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Denali Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Denali Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Denali Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (298.46) | (313.38) | |
| Return On Tangible Assets | (0.13) | (0.13) | |
| Return On Capital Employed | (0.18) | (0.19) | |
| Return On Assets | (0.13) | (0.13) | |
| Return On Equity | (0.14) | (0.15) |
Things to note about Denali Therapeutics performance evaluation
Checking the ongoing alerts about Denali Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Denali Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Denali Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 330.53 M. Net Loss for the year was (145.22 M) with loss before overhead, payroll, taxes, and interest of (250.27 M). | |
| Denali Therapeutics currently holds about 1.07 B in cash with (357.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66. | |
| Denali Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Denali Therapeutics Inc. Receives 38.90 Consensus Target Price from Brokerages - MarketBeat |
- Analyzing Denali Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Denali Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Denali Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Denali Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Denali Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Denali Therapeutics' stock. These opinions can provide insight into Denali Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |